• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 14
  • 2
  • 1
  • 1
  • Tagged with
  • 24
  • 11
  • 9
  • 9
  • 8
  • 7
  • 6
  • 6
  • 6
  • 6
  • 6
  • 6
  • 5
  • 5
  • 4
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
1

FGFR-Alterationen in primären und oligometastasierten kolorektalen Karzinomen / FGFR alterations in primary and oligometastatic colorectal cancer

Fromme, Julia Elisabeth 17 November 2020 (has links)
No description available.
2

The proteoglycan perlecan regulates long bone growth through interactions with developmental proteins in the growth plate

Smith, Simone Marsha-Lee 01 June 2007 (has links)
Perlecan is the major heparan sulfate proteoglycan (HSPG) in growth plate cartilage and is critical for growth plate chondrocyte proliferation and proper skeletal development. Its core protein and attached chondroitin sulfate (CS) and heparan sulfate (HS) chains mediate interactions with many diverse proteins. Fibroblast growth factor (FGF)-2 and FGF-18 are other regulators of chondrocyte proliferation in the growth plate. Additionally, FGF-18 controls the hypertrophy and cartilage vascularization necessary for endochondral ossification. The research presented in this dissertation aimed to identify known and novel perlecan-binding proteins that are endogenous to the growth plate and to characterize their interactions with perlecan. FGF-2 (known to bind HSPGs) bound to perlecan in both a cationic filtration (CAF) assay and an immunoprecipitation (IP) assay primarily via the HS chains on perlecan. When digested with chondroitinase ABC to remove its CS chains, perlecan augmented binding of FGF-2 to the FGFR-1 and FGFR-3 receptors and increased FGF-2 -stimulated proliferation in BaF3 cells expressing these FGF receptors. Thus, growth plate perlecan binds to FGF-2 by its HS chains but can only deliver FGF-2 to FGF receptors when its CS chains are removed. FGF-18 (known to bind to heparin and to heparan sulfate from some sources) bound to growth plate perlecan. This binding was unchanged by chondroitinase or heparitinase digestion of perlecan, indicating that perlecan GAGs are not involved in FGF-18 binding. FGF-18 bound equally to recombinant domains I-III of perlecan (Alt1) and to full-length perlecan purified from the growth plate. Additionally, FGF-18 bound equally to recombinant domain III of perlecan, to Alt1 and to Alt2 (a domain I-III variant with no heparan sulfate). Therefore, binding sites for FGF-18 are present in domain III of perlecan. Affinity chromatography isolated histone H3 as a perlecan-binding protein from the chondrocyte matrix. CAF assays confirmed the interaction as specific, dependent primarily on HS chains of perlecan, although CS chains and the perlecan core were also involved. Immunohistochemistry detected perlecan and histone H3 colocalized in growth plate cartilage. These results can help us better understand the growth factor-independent control that perlecan exerts on endochondral ossification and, therefore, long bone growth.
3

The human Klotho VS variant: focus on the processing and function of the V, S and VS isoforms

Tucker Zhou, Tracey Beth 24 September 2015 (has links)
Klotho (KL), an anti-aging protein, attracted interest in the aging field because of the dramatic phenotype of KL deficient mice and its connection to signaling pathways implicated in aging. The KLVS variant consists of the F352V (KLV) and C370S (KLS) substitutions. It was detected in genome wide association studies (GWAS) that linked it to alterations in longevity and disease risk. The molecular mechanism(s) underlying these associations are unknown. To understand how KL increases the risk of age-related diseases, the studies in this dissertation investigated whether expression of the KLVS variant, when compared to wildtype (KLWT), displays differences in processing, protein-protein interactions and enzymatic activity. Differences in processing were evaluated by studying changes in shedding, half-life and plasma membrane localization of KL variants. The decrease in KLV shedding, as measured by the intracellular: extracellular ratio, were explained by a decreased half-life. This decreased half-life is potentially due to decreased KLV plasma membrane localization, which is attenuated by co-expression of dominant negative dynamin, suggesting a role of endocytosis in these differences. To assess whether there are changes in KLVS protein-protein interactions, differences in dimerization were measured by Blue Native gel electrophoresis and cross-linking. KLV dimerization was increased while KLS and KLVS variants decreased dimerization. Co-immunoprecipitation of tagged KL assessed whether these changes were due to alterations in homodimerization. The presence of KLVS in dimers decreased the levels of immunoprecipitated KL suggesting KLVS decreases homodimerization. Changes in heterodimerization of KLVS with fibroblast growth factor receptor (FGFR) 1c were also investigated through co-immunoprecipitation. KLVS increased heterodimerization with FGFR1c. Addition of FGF23, for which KL is a co-receptor, showed that KLVS increases FGF signaling downstream of FGFR1c. To determine differences in enzymatic activity of KLVS, 4-metylumbelliferyl-beta-D-glucuronide was used to measure alterations in glucuronidase activity. Results showed that KLVS had decreased enzymatic activity compared to KLWT. These findings are the first to show that KLVS leads to differences in function as demonstrated by decreased homodimerization and enzymatic activity and increased heterodimerization with FGFR1c. Given the association of KLVS with disease and longevity, these results suggest that these functions are integral in KL's anti-aging role in humans.
4

Fibroblast Growth Factor Receptor (FGFR) Inhibitors: A Review of a Novel Therapeutic Class

Weaver, April, Bossaer, John B. 01 April 2021 (has links)
Comprehensive genomic profiling has an emerging role in cancer therapeutics. As treatment options remain needed for advanced cancers, patients are relying increasingly more on tumor genomic alterations as possible targets for cancer treatment. Frequent tumor fibroblast growth factor receptor (FGFR) alterations are seen in many cancers, and include genetic amplifications, mutations, rearrangements and fusions. FGFR inhibitors target these receptor alterations and show promise as a drug class. Currently 2 medications are currently FDA approved: erdafitinib and pemigatinib. Through the FDA accelerated approval process, erdafitinib is indicated to treat metastatic urothelial carcinoma with FGFR2 and FGFR3 alterations, whereas pemigatinib is indicated to treat unresectable cholangiocarcinoma with FGFR2 alterations. Despite growing knowledge about such advanced cancers, treatment is usually palliative. With multiple FGFR inhibitors in the pipeline, further FDA approvals are possible, and it is likely their role in therapy will extend to other cancer types. This review outlines erdafitinib, pemigatinib, their role in cancer, as well as outlining the possible future use of other FGFR inhibitors in urothelial carcinoma, cholangiocarcinoma, and other malignancies.
5

Fibroblast Growth Factor Receptor (FGFR) Inhibitors: A Review of a Novel Therapeutic Class

Weaver, April, Bossaer, John B. 01 January 2020 (has links)
Comprehensive genomic profiling has an emerging role in cancer therapeutics. As treatment options remain needed for advanced cancers, patients are relying increasingly more on tumor genomic alterations as possible targets for cancer treatment. Frequent tumor fibroblast growth factor receptor (FGFR) alterations are seen in many cancers, and include genetic amplifications, mutations, rearrangements and fusions. FGFR inhibitors target these receptor alterations and show promise as a drug class. Currently 2 medications are currently FDA approved: erdafitinib and pemigatinib. Through the FDA accelerated approval process, erdafitinib is indicated to treat metastatic urothelial carcinoma with FGFR2 and FGFR3 alterations, whereas pemigatinib is indicated to treat unresectable cholangiocarcinoma with FGFR2 alterations. Despite growing knowledge about such advanced cancers, treatment is usually palliative. With multiple FGFR inhibitors in the pipeline, further FDA approvals are possible, and it is likely their role in therapy will extend to other cancer types. This review outlines erdafitinib, pemigatinib, their role in cancer, as well as outlining the possible future use of other FGFR inhibitors in urothelial carcinoma, cholangiocarcinoma, and other malignancies.
6

Molecular mechanism of the Fibroblast Growth Factor Receptor, egl-15, and α-integrin receptor, ina-1, in gland cell migration during embryonic development of the Caenorhabditis elegans pharynx

Kim, Shinhye 21 January 2015 (has links)
Caenorhabditis elegans is a powerful tool to study cellular migration and morphogenesis during organ development. During pharynx development, the dorsal gland cell, g1p, is born in the anterior aspect of the pharyngeal primordium and undergoes a form of morphogenesis called retrograde extension. egl-15, the single Fibroblast Growth Factor Receptor (FGFR) in C. elegans and ina-1, one of two α-integrin receptors, are both required for the proper extension or migration of g1p cell. Mutations in either egl-15 or ina-1 show similar gland cell over-migration defects where the gland cell body migrates past the terminal bulb and is located in proximity of the intestine. The kinase domain of EGL-15 was found to be required for migration and transgenic rescue strategies were used to determine the tissue of EGL-15 function. RNA interference was used to determine if egl-15 and ina-1 are functioning in the same pathway to regulate gland cell migration. / February 2015
7

Expression and Purification of Unlabelled and Isotopically Labelled Human Fibroblast Growth Factor-1 and its Receptor Relevance in Cancer Research

Filani, Oluwadamilola 01 October 2015 (has links)
Studies show that fibroblast growth factors (FGFs) control variety of cellular activities such as mitosis, cell differentiation, survival and angiogenesis. The FGF family consists of 23 different heparin-binding proteins. One of the most intensively studied members is human FGF-1 (hFGF-1) because of its critical role in the formation of blood vessels and cell proliferation in some types of cancer. The biological activities of FGFs are primarily mediated via interactions with fibroblast growth factor receptors (FGFR) and are a potent target in cancer. In this study, we report an efficient affinity column purification of hFGF-1 and the D2 domain of FGFR-2 from bacterial expression followed by SDSPAGE analysis. Steady state fluorescence results showed that both proteins were in their native conformation. The 1 H-15N HSQC NMR analysis of hFGF-1 was further performed. The data confirmed the purity and well-conserved native state of the protein. The findings of this study can be used in designing hFGF-1 antagonists with competitive inhibition characteristics. These antagonists could result in possible inhibition of hFGF-1 cell proliferation and angiogenesis associated in tumorigenesis.
8

Mechanisms of Transdifferentiation and Regeneration

Madhavan, Mayur C. 02 December 2005 (has links)
No description available.
9

The Role of Fibroblast Growth Factor-2 Isoforms in Ischemia-reperfusion Injury and Cardioprotection

Liao, Siyun 23 April 2008 (has links)
No description available.
10

PHARMACOLOGICAL TARGETING OF FGFR SIGNALING TO INHIBIT BREAST CANCER RECURRENCE AND METASTASIS

Saeed Salehin Akhand (8771426) 29 April 2020 (has links)
Breast cancer (BC) is one of the deadliest forms of cancers with high incidence and mortality rates, especially in women. Encouragingly, targeted therapies have improved the overall<br>survival and quality of life in patients with various subtypes of BC. Unfortunately, these first-line therapies often fail due to inherent as well as acquired resistance of cancer cells. Treatment evading cancer cells can exhibit systemic dormancy in patients over a long period of time without manifesting any symptoms. In a suitable environment, these undetected disseminated tumor cells can relapse in the form of metastasis. Therefore, it is essential to understand the mechanisms of<br><div>BC recurrence and to develop durable therapeutic interventions to improve patient’s survival. In this dissertation work, we studied fibroblast growth factor receptors (FGFR), as therapeutic targets to treat the recurrence of drug-resistant and immune-dormant BC metastasis. <br></div><div><br></div><div>The HER2 subtype of BC is characterized by the overexpression of human epidermal growth factor receptor 2 (HER2), which drives elevated downstream signaling promoting tumorigenesis. Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate in which an anti-HER2 antibody targets HER2 overexpressing tumor cells and delivers a highly potent microtubule inhibitor. Using novel models of minimal residual disease (MRD) following T-DM1 treatments, we found that epithelial to mesenchymal transition is a critical process for cells to persist the TDM1 treatments. The upregulation of FGFR1 may facilitate insensitivity to T-DM1. Our data also showed that FGFR1 overexpression in HER2+ tumors leads to a higher incidence of recurrence, and these recurrent tumors show sensitivity towards covalent inhibition of FGFR. <br></div><div><br></div><div>In addition to drug-induced MRD in the primary tumor sites, disseminated tumor cells (DTCs) can demonstrate dormant phenotype via maintaining an equilibrium with immunemediated tumor clearance. Factors affecting such equilibrium may contribute to the recurrence of breast cancers metastasis. We show that such immune-mediated dormancy can be modeled with the 4T07 tumors. These tumors display immune-exclusion phenotypes in metastatic pulmonary organs. The inhibition of FGFR modulates the immune cell compositions of pulmonary organs favoring anti-tumor immunity. However, inhibition of FGFR may also affect T cell receptor downstream signaling, resulting in the inhibition of cytolytic T cell’s function. Finally, we report that combination therapy using the FGFR kinase inhibitor and an immune checkpoint blockade showed effective targeting of metastatic 4T07 tumors. <br></div><div><br></div><div>FGFR signaling as a therapeutic target in various tumors has been an active focus of cancer research. In this dissertation work, we have expanded our understanding of the role of FGFR in the recurrence of drug-resistant breast cancers as well as in the maintenance of an immune evasive microenvironment promoting pulmonary growth of tumors. Moreover, we presented evidence that it is possible to repurpose FGFR targeted therapy alone or in combination with checkpoint blockades to target recurrent metastatic BCs. In the future, our novel models of minimal residual diseases and systemic immune dormancy may act as valuable biological tools to expand our understanding of the minimal residual disease and dormant tumor cells.</div>

Page generated in 0.0608 seconds